Glycogen synthase kinase 3 beta intronic DNA (GSK3B intronic DNA)

GSK3β intronic DNA refers to the non-coding genomic sequences located within the Glycogen Synthase Kinase 3 Beta (GSK3B) gene. While the GSK3β protein is a primary therapeutic target for bipolar disorder, schizophrenia, and certain cancers, these intronic regions are critical regulatory elements that dictate the protein's expression and structural diversity through alternative splicing (1.2.1, 1.3.1). Specifically, intronic single nucleotide polymorphisms (SNPs), such as rs6438552 in intron 5, have been identified as regulators of splice acceptor site selection, which can result in the production of GSK3β isoforms lacking specific exons and possessing altered enzymatic activity (1.2.1, 1.3.1). In a clinical context, GSK3β intronic DNA is primarily studied as a pharmacogenomic locus rather than a direct drug-binding target. Variations within these sequences are strongly associated with a patient's therapeutic response to mood stabilizers like lithium; for instance, certain intronic haplotypes are linked to improved lithium efficacy in bipolar patients (1.3.2, 1.3.4). Furthermore, these regions influence the pathogenesis of neurodegenerative diseases by modulating the kinase's ability to phosphorylate microtubule-associated proteins like tau (1.2.1). Understanding the variations in GSK3β intronic DNA is essential for developing personalized medicine approaches and identifying biomarkers for psychiatric and neurological conditions (1.3.5).

Other names

GSK3B intronsGSK3B intronic polymorphismsrs6438552 locusGSK3B regulatory DNA

Modulation of GSK3B protein expression levels and alternative splicing patterns, which in turn affects the kinase activity available to phosphorylate downstream substrates like tau and beta-catenin.